HARVARD BIOSCIENCE INC (HBIO) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, HARVARD BIOSCIENCE INC's filing signal turned negative.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications, including research, drug discovery, bioproduction, and preclinical testing. Operating globally with a presence in the United States, Europe, and China, the company serves academic institutions, government laboratories, and pharmaceutical and biotechnology companies. Its product portfolio is divided into Cellular and Molecular Technologies (CMT) and Preclinical segments, with CMT accounting for approximately 46% of 2025 revenues and Preclinical for 54%. The company also distributes third-party products, which represented about 13% of 2025 revenue. Harvard Bioscience is strategically evolving from a tools provider to an enabler of Translational Medicine, focusing on bridging laboratory research and clinical success.

Revenue is driven by the sale of instruments, equipment, accessories, consumables, software, and services across its CMT and Preclinical product families, as well as the distribution of third-party products. Sales are conducted through direct channels and distributors.